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Abstract
Background The multiple endocrine neoplasia type 1 syndrome (MEN1) natural history is poorly evaluated, and few
single-institution experiences about hereditary gastroenteropancreatic neuroendocrine tumors (GEP-NET) are
reported. Our purpose is to analyze the role of GEP-NET in MEN1-related death, as well as the behavior of these
lesions during follow-up.
Methods The study population consists of 77 patients diagnosed with MEN1 GEP-NET, regularly followed up since
1990. Extensive clinical data were prospectively recorded. Statistical analysis was performed both on the whole
population of 77 patients and on two subgroups including patients who, during the long lasting study period,
underwent GEP-NET surgery (50 pts) and who did not (27 pts), respectively.
Results Twenty-five males (32.5%) and 52 females (67.5%) were enrolled. Sixty-four patients had MEN1 family
history (83.1%), and genetic mutation was detected in 67 cases (87%). The mean age at GEP-NET diagnosis was
41.4 years (SD = 13.6); 16 patients (20.8%) had GEP-NET diagnosed before age 30 and 12 cases (15.6%) before
1996. The mean interval time between MEN1 diagnosis and GEP-NET detection was 5.7 years (range -11/37;
SD = 8.1 years). Overall, the mean follow-up time from MEN1 diagnosis was 15.8 years (SD = 9.7 years) and from
GEP-NET diagnosis was 9.6 years (SD = 6.9 years). Gastrinoma was the most frequent functioning GEP-NET and
pancreatoduodenectomy the most adopted surgery. GEP-NET progression affected 12 patients within the non-
surgical group, while 18 subjects developed progression after surgery.
Conclusions Our single-center data provide information on epidemiologic, clinical and pathological features of GEP-
NET in MEN1 making possible to clarify their natural history.
Introduction
Multiple endocrine neoplasia type 1 syndrome (MEN1) is an
autosomal dominant genetic disorder. MEN1 gene is located on
chromosome 11q13, and it was identified in 1997 [1–5].
Gastroenteropancreatic neuroendocrine tumors (GEP-NET)
arise early in patients affected by MEN1. Two forms of GEP-
NET are described in MEN1: non-functioning tumors (NF),
characterized by the absence of production and/or release of
neuroendocrine polypeptides, and functioning tumors, produc-
ing active hormones such as gastrin, insulin, vasoactive
intestinal polypeptide (VIP), glucagon or somatostatin, giving
rise to a typical clinical syndrome [6, 7].
The GEP-NET malignancy is variable, depending not
only on the size but also on histological type; it seems to be
low for lesions smaller than 2 cm in diameter and for
insulinomas (12–20%), but it is relevant for NF tumors and
gastrinomas (about 70%) [6–9].
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Unlike sporadic GEP-NET, many small endocrine
tumors (condition referred to as microadenomatosis) are
generally present in the pancreas of patients with MEN1.
The pancreatic microadenomas are often associated with
macrotumor/s (diameter C 1 cm), some of which may be
functional. The GEP-NET penetrance in MEN1 is high,
reaching 80–90% at 60 years of age, similarly to primary
hyperparathyroidism (PHPT) [6–11].
Different imaging examinations are conducted in order
to assess GEP-NET progression. However, endoscopic
ultrasound (EUS) is an operator-dependent second-level
procedure and trans-abdominal ultrasound (US), computed
tomography (CT) and magnetic resonance imaging (MRI)
have low sensitivity in detecting lesions less than 1 cm in
diameter, thus leaving most of the small GEP-NET
potentially unrecognized [12–24].
Furthermore, in patients affected by MEN1, even in
presence of functioning GEP-NET, the frequent association
of other non-functioning pancreatic lesions prevents the
localization of the tumor responsible for hormone pro-
duction through purely morphological techniques.
Although scientific progress occurred in both MEN1
GEP-NET diagnosis and treatment, the natural history of
the disease remains poorly evaluated [10, 25–28].
The purpose of this study is to analyze the role of GEP-
NET in MEN1-related death, as well as the behavior of
these lesions during follow-up.
Materials and methods
The study population consists of 77 patients affected by
MEN1 diagnosed with GEP-NET, belonging to various
families, regularly followed up at the Department of Sur-
gery and Translational Medicine, University Hospital
Careggi, Florence, Italy, in the period 1990–2014. Clinical
data were prospectively recorded in an electronic database
after signature of informed consent by all the study par-
ticipants and after obtaining ethical approval by the local
Experts Committee of Careggi Hospital. Family trees have
been established for all index cases and used to identify the
affected family members. According to international
guidelines [3, 29], the following criteria were considered
for GEP-NET diagnosis in MEN1:
– Patients with a detected MEN1 mutation affected by
GEP-NET, either associated or not with other neuroen-
docrine tumors (parathyroid, pituitary, adrenal, thymic,
bronchial, gastric lesions).
– Patients with clinical/radiologic evidence of GEP-NET
belonging to a known MEN1 family with at least one
first-degree-relative affected by a neuroendocrine
tumor.
– Patients with negative genetic test and without MEN1
family history but affected by GEP-NET plus PHPT
and/or pituitary adenoma.
The diagnostic criteria to define the presence of GEP-
NET in MEN1 and thus to establish the inclusion into the
present study were clinical (medical history and physical
examination, blood tests and stimulation test with secretin)
and/or radiologic [US, CT, MRI, somatostatin receptor
scintigraphy (SSRS), EUS] and/or pathological.
Each patient underwent an extensive examination
regarding signs and symptoms due to GEP-NET. A medi-
cal history was meticulously collected.
Time of MEN1 onset was defined as the time of the first
clinical manifestation of MEN1 (renal colic, pituitary dis-
ease, hormonal syndrome or radiologic evidence of GEP-
NET, etc.) or, in case of asymptomatic patients, the time
when the disease was detected by biochemical screening or
genetic test.
Clinical visit, blood examinations for baseline
enteropeptidase and hormones [neuron-specific enolase
(NSE); chromogranin A (CgA); pancreatic polypeptide
(PP); somatostatin (SS); vasoactive intestinal polypeptide
(VIP); glucagon; insulin and c-peptide, gastrin and basal
acid production (BAO)] were performed yearly at our
Center. US was performed every 12 months, while
abdominal CT or MRI and EUS were performed every
12–24 months, SSRS as needed. The secretin stimulation
test was performed every 12–18 months by intravenous
injection of 75 IU synthetic human secretin (Secrelux,
Goldman, Neuss, Germany). Blood samples were taken at
baseline, 2.5, 5, 7.5, 10, 15 and 30 min after secretin
administration.
This scheduled follow-up (clinical, biochemical and
radiologic) was adopted to evaluate or diagnose pituitary
tumors, primary hyperparathyroidism (PHPT), GEP-NET
and/or adrenal gland disease. When suspected, the presence
of liver metastasis was confirmed by histology [high
prevalence in patients with MEN1 of focal nodular
hyperplasia (FNH)]; thoracic CT and/or SSRS and/or MRI
and histology were adopted for thymic carcinoid evalua-
tion; the presence of bronchial carcinoids was assessed by
fibrobronchoscopy and/or thoracic X-ray and/or CT and/or
SSRS and/or MRI and histological confirmation; gastric
carcinoid was diagnosed by upper digestive endoscopy
with biopsy. MEN1-associated skin lesions (collagenomas,
angiofibromas, lipomas), as well as any other neoplastic
lesion, were recorded in the electronic dataset.
Surgical intervention for GEP-NET was indicated in
case of either clinical syndrome or imaging showing
lesions over 1.5–2 cm in diameter or significant increase in
volume (a doubling of tumor size exceeding 1 cm over a
12-month interval) (Fig. 1). The preoperative finding of
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liver lesion/s was not considered a contraindication. At
surgery, intraoperative US evaluating both pancreas and
liver was performed. In patients with gastrinoma, a par-
ticular attention was deserved to the duodenum: Kocher
maneuver, palpation and transillumination were performed.
All surgical operations aimed to remove every func-
tioning GEP-NET and all the eventually present con-
comitant macroscopic lesion/s found within the pancreas or
in regional lymph nodes and liver.
The number and size of each measurable GEP-NET
described at pathological examination were recorded.
The occurrence of new GEP-NET or a significant
increase in volume ([25%) or the evidence of secondary
lymph node involvement or liver metastasis was defined as
disease progression, regardless of the presence or absence
of a typical endocrine syndrome. In the surgical cohort,
GEP-NET progression was evaluated from the time of
primary surgery. In presence of disease progression to
liver, we indicated surgery whenever possible, while
medical therapy (with a strict radiologic follow-up) was
performed in presence of major liver involvement in
patients with scarce performance status.
Adrenalectomy was indicated for lesions either larger
than 4 cm in diameter or having atypical or suspicious
radiologic features and 1–4 cm in diameter, or showing
rapid growth.
Initial clinical status as well as follow-up data including
clinical features, secretin test, imaging findings, surgical
procedures, medical therapies prescribed for GEP-NET
was recorded for each patient.
Data analysis
Statistical analysis was performed on all collected data:
Regarding time-related variables, the time of the event was
defined as the interval between the birth (time zero) and the
occurrence of the studied event (MEN1 diagnosis, evidence
of GEP-NET, GEP-NET progression, death). The follow-
ing factors were analyzed in relationship to GEP-NET
progression and mortality: age at MEN1 diagnosis, age at
GEP-NET diagnosis and at surgery; age over 30 at MEN1
diagnosis; age over 30 at GEP-NET diagnosis; MEN1
diagnosis before 1996; GEP-NET diagnosis before 1996;
family history; gender; presence of MEN1 mutation; type
of mutation; MEN1 diagnosis/GEP-NET diagnosis interval
Fig. 1 Indications to surgery according to the different preoperative
clinical characteristics of GEP-NET
Table 1 Data of the study cohort (77 patients)
No. of patients 77 (25M, 52F)
Positive family history 83%
Mean age at MEN1 diagnosis 35.3 years (SD = 12.8) under 30 = 28 (36.4%) diagnosed before 1996 = 30 (38.9%)
Mean age at GEP-NET diagnosis 41.4 years (SD = 13.6) under 30 = 16 (20.8%) diagnosed before 1996 = 12 (15.6%)
Mean MEN1 GEP-NET diagnostic interval time 5.7 years (range -11/36; SD = 8.1 years)
Diagnostic tool Imaging: 90.9%; biochemical assay: 9.1%
Associated syndromic features
PHPT 70 (90.9%)
Pituitary adenoma 47 (61%)
Adrenal tumor 9 (11.7%)
Bronchial carcinoid 6 (7.8%)
Mean follow-up from MEN1 diagnosis 15.8 years (SD = 9.7)
Mean follow-up from GEP-NET diagnosis 9.6 years (SD = 6.9)
Mortality 4 patients (5.2%)
Causes of death
GEP-NET progression 2 cases (2.6%)
Thymic carcinoid 1 case (1.3%)
Pulmonary embolism 1 case (1.3%)
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time; GEP-NET diagnosis/surgery interval time; age over
50 at the last follow-up; positive preoperative secretin test;
initial syndrome symptoms; type of GEP-NET (gastri-
noma, insulinoma, other); surgery for GEP-NET; presence
of lymph node metastasis at surgery; presence of liver
metastasis at surgery; surgery before 1996; type of surgery
[pancreatoduodenectomy (PD), corporocaudal pancreatic
resection; GEP-NET enucleation; total pancreatectomy;
PD plus enucleation; corporocaudal resection plus enucle-
ation; liver surgery for metastasis or FNH]; surgical com-
plications; maximal diameter of lesions\ or[ 1.5 cm;
adrenal surgery; carcinoid exeresis; re-operation for
recurrent disease; positive secretin test at surgical follow-
up; concordance between radiologic imaging and secretin
test; disease progression; interval time between GEP-NET
diagnosis and progression. This statistical analysis was
conducted both on the whole population of 77 patients
overall and on the subgroups of operated and not-operated
cases.
PHPT was not an object of the statistical analysis
because almost all the patients were affected.
All the clinical variables were considered time-depen-
dent covariates. The time cutoff 1996 for the variable
MEN1 or GEP-NET diagnosis was arbitrarily chosen
according to the change in diagnostic and therapeutic
strategies for patients affected by MEN1 syndrome, due to
the positional cloning of MEN1 gene.
For all the analysis performed, p\ 0.05 was considered
significant.
Results
Our cohort included 77 patients with MEN1, 25 males
(32.5%) and 52 females (67.5%). Clinical data are reported
in Table 1. A genetic mutation was detected in 67 cases
(87%) (Fig. 2a).
The mean age at MEN1 diagnosis was 35.3 years
(SD = 12.8 years); the mean age at GEP-NET diagnosis
was 41.4 years (SD = 13.6 years). In seven patients
(9.1%), GEP-NET diagnosis relied on biochemical basis
(secretin test positive for one or more entero-hormones),
while in 70 patients (90.9%) imaging examinations con-
firmed the diagnosis. However, 20 of these patients
(28.6%) during the study follow-up were not eligible for
surgery based on both clinical and radiologic criteria.
Fig. 2 a Pie chart showing the
percent distribution of MEN1
mutations in the 77-patient
cohort and b pie chart showing
the primary surgery performed
in 50 cases
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Overall, the mean follow-up time from MEN1 diagnosis
was 15.8 years (SD = 9.7 years), and the mean time from
GEP-NET diagnosis was 9.6 years (SD = 6.9 years).
Surgical cohort
Data regarding the group of patients who required GEP-
NET surgery (n = 50, 71.4%) are described in Tables 2
and 3. The mean age at surgery was 40.6 years
(SD = 12.4). A PD was performed in 19 patients (38%),
corporocaudal resection in 13 cases (26%), enucleation of
one or more pancreatic lesions in 4 patients (8%), PD plus
enucleation in 6 cases (12%), corporocaudal resection plus
enucleation of pancreatic head tumors in 3 patients (6%),
total pancreatectomy only in one female patient (2%)
affected by multiple (n. 23) lesions found within all the
pancreatic gland, most of which[1.5 cm in diameter. The
same patient was also affected by gastrinomas metastasis
on the VII liver segment, radically treated. Four patients
(8%) required a different surgical treatment: one underwent
ileal resection for NF GEP-NET; the other three, presenting
duodenal gastrinomas, underwent gastroduodenal resec-
tion, partial duodenectomy and endoscopic exeresis,
respectively (Fig. 2b). At primary surgery, liver involve-
ment (minor/segmental) was found in 7 patients (14%):
Synchronous resection was possible in all cases; however,
histological examination of the specimen showed FNH in 4
of these patients (57.1%). Nine patients (18%) underwent
adrenal surgery.
The evaluation of the preoperative clinical syndrome
combined with pathological and immunohistochemical
analysis on the specimen, allowed the identification of 28
patients (56%) affected with gastrinoma, 15 (30%) with
insulinoma, 2 (4%) with vipoma, 1 (2%) with
glucagonoma. The other 4 patients (8%) were affected by
non-functioning GEP-NET only.
Analyzing these 50 operated patients, a mean of 17.12
NF lesions per patient (range 0–62) were described at the
macroscopic plus microscopic examination of the surgical
specimen.
Postoperative complications and diabetes mellitus inci-
dences are reported in Table 3.
Within the surgical subgroup, a GEP-NET oncologic
progression occurred in 16 patients (32%) after a mean
postsurgical follow-up of 6.6 years (range 1–17 years); in all
cases, it was assessed by imaging studies (CT, MRI, SSRS,
EUS, US), while secretin test was positive in only 6 cases
(37.5%). Two patients (12.5%) died due to unoperable liver
progression. Only three patients (6%) required surgery for
GEP-NET progression: The first case was a young woman
who, four years after PD, developed para-aortic lymph node
metastasis from gastrinoma; the second patient, 2 years after
PD performed to treat Zollinger–Ellison syndrome (ZES),
developed hepatobiliary tree gastrinoma with ZES recur-
rence, treated with hepatic resection of segments V-VIII; the
third patient, instead, after a first enucleation of a pancreatic
head lesion in 1995, underwent multiple operations: In 1996
further enucleation associated with liver surgery for lesions
which were shown to be FNH; in 2004 duodenal mucosec-
tomy to treat ZES; in 2008 ampullectomy, then in 2009 PD
associated with radiofrequency (RF) ablation of a single
small liver metastasis. For the other 11 patients (68.7%), the
presence of residual pancreatic lesions did not represent,
after 3.8 years (range 2–7 years) mean follow-up from the
detection of GEP-NET progression, a surgical indication,
being the symptoms manageable with medical therapy (so-
matostatin analogues) or the lesion smaller than 1.5–2 cm in
diameter.
Table 2 Clinical features of surgical group by type of GEP-NET primary operation
Type of operation No. pts Clinical syndrome Mean age at surgery Postoperative
complications
Postoperative
progression
PD ± enucl. 25 19 ZES
3 hypoglycemia
1 WDHAa
2 symptomless
45.39 years
(range 28.02–63.22)
9 (36%)
5 surgically treated
4 medically treated
6 (24%)
Corporocaudal resection ± enucl. 16 1 ZES
7 hypoglycemia
8 symptomless
37.19 years
(range 19.34–62.76)
9 (56%)
3 surgically treated
6 medically treated
4 (25%)
Enucleation only 4 1 ZES
2 hypoglycemia
28.87 years
(range 17.44–44.21)
1 (25%) surgically treated 3 (75%)
Total pancreatectomy 1 1 ZES 45.03 years 1 (100%) medically treated 0 (0%)
Other 4 2 ZES
2 symptomless
51.10 years
(range 41.02–69.41)
0 (0%) 2 (50%)
a WDHA watery diarrhea, hypokalemia, achlorhydria
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Concerning the 77 patients analyzed in our database, 4
of them died a mean of 5 and 5.7 years after diagnosis of
MEN1 and GEP-NET, respectively (range 0.1–11 years).
All of those patients had undergone surgery for GEP-NET:
the first patient, operated on of gastroduodenal resection for
ZES in 1989, died in 2000 aged 52 for progression of
thymic carcinoid; the second, 72-year-old, died in 2001,
9 years after PD, due to liver metastases from GEP-NET;
the third, operated at the age of 61 for liver metastases from
NF GEP-NET, died in 2003, 3 years after surgery; the
fourth patient, aged 53, died in 2003 because of pulmonary
embolism during the short-term postoperative course after
PD associated with liver resection for synchronous liver
metastases.
Non-surgical cohort
A separate analysis was also performed on the 27 patients
(28.6%) who did not meet surgical criteria or had not yet
undergone surgery for GEP-NET at the end of this study
Table 3 Surgical cohort data (50 patients)
No. of patients 50 (71.4%)
Mean age at MEN1 diagnosis 35.1 years (SD = 12)
Mean age at GEP-NET diagnosis 39.3 years (SD = 12.3)
Mean MEN1 GEP-NET diagnostic interval time 1.3 years (SD = 2.9 years)
Positive secretin test 31 cases (62%)
Symptoms related to functioning GEP-NET syndrome 38 cases (76%)
Mean follow-up from MEN1 diagnosis 16.6 years (SD = 9.3)
Mean follow-up from GEP-NET diagnosis 12.0 years (SD = 7.3)
Mean age at surgery 40.6 (SD = 12.4)
Type of surgery
PD 19 (38%)
Corporocaudal resection 13 (26%)
Enucleation 4 (8%)
PD ? enucleation 6 (12%)
Corporocaudal resection ? enucleation 3 (6%)
Total pancreatectomy 1 (2%)
Further abdominal surgery 4 (8%) [1 ileal resection; 3 gastroduodenal surgery]
Liver resection 7 (14%) [FNH in 4 cases, 57.1%]
Adrenal surgery 9 (18%)
Postoperative complications 20 pts (40%)
Conservatively treated 11 pts (55%)
Surgically treated 9 pts (45%) (bleeding 1; pancreatitis/fistula 5; anastomotic
leakage 2; internal hernia 1)
Postoperative diabetes mellitus 6 pts (12%)
Pathological examination
Gastrinomas 28 pts (56%)
Insulinomas 15 pts (30%)
Vipomas 2 pts (4%)
Glucagonoma 1 pt (2%)
NF only 4 patients (8%)
Mean no. of NF per patient 17.12 (range 0–62)
Maximum GEP-NET diameter Range 0.1–5 cm;[1.5 cm in 16 cases (32%)
Liver metastases 3 pts (6%)
Lymph node metastases 10 pts (20%)
GEP-NET progression 16 pts (32%)
Increase in number or syndrome development 10 pts (62.5%)
Increase in volume 2 pts (12.5%)
Evidence of liver or lymph-nodal metastasis 4 pts (25%)
Mean progression time 6.6 years (range 1–17)
World J Surg
123
(Table 4). They were 19 females (70.4%) and 8 males
(29.6%) with a mean age at diagnosis of MEN1 of
35.6 years (SD = 14.4), mean age at GEP-NET diagnosis
of 45.4 years (SD = 15.3) and a mean age at last follow-up
of 50.6 years (SD = 15). All the patients of this subgroup
were alive at the end of the study. Family history of MEN1
was present in 23 cases (85.2%); MEN1 mutation was
identified in 22 patients, respectively, in exon 2 (5 cases), 3
(2 cases), 4 (1 case), 5 (1 case), 6 (1 case), 8 (5 cases), 9 (4
cases), 10 (4 cases), and a double mutation was found in 2
patients. At diagnosis of GEP-NET, a clinical syndrome
was present in only one of them (3.7%) who showed ZES,
but a secretin test was positive in 21 patients (77.8%); two
patients (7.4%) did not performed the test and had radio-
logic diagnosis of GEP-NET.
According to the data related to the secretin test, a
positive test for gastrinoma was present in 12 cases (with a
simultaneous increase in the values of glucagon and CgA
in 3 cases, PP in another patient, PP and CgA in another
case).
In the non-surgical subgroup of 27 patients, GEP-NET
progression occurred in 12 cases (44.4%), average
3.33 years after GEP-NET diagnosis (range 1–13 years). In
three of these cases, the size of GEP-NET or the occur-
rence of an uncontrollable syndrome indicated surgical
treatment, but two patients refused surgery (starting
somatostatin analogues therapy) and the other one had not
yet undergone GEP-NET surgery at the end of the study
period.
Statistical analysis
Adopting the log-rank method (Mantel-Cox) on all 77
patients (Table 5), variables significantly associated with
GEP-NET progression (considering follow-up after MEN1
diagnosis) were: male gender, MEN1 mutation in exon 8,
diagnosis of MEN1 before 1996, surgery for GEP-NET,
primary enucleation, PD ? enucleation, secretin test posi-
tive at follow-up; diagnosis of GEP-NET performed before
1996 did not reach statistical significance (p = 0.056).
Figure 3a shows the Kaplan–Meier curve for progression
free survival of all 77 patients, adopting as follow up the
time from GEP-NET diagnosis.
Adopting the log-rank method (Mantel-Cox) on 50
patients operated for GEP-NET, variables significantly
associated with GEP-NET progression (follow-up calcu-
lated after GEP-NET diagnosis) were: MEN1 mutation in
exon 8 (p = 0.011), familiar MEN1 (p = 0.022), diagnosis
of MEN1 performed before 1996 (p = 0.001), enucleation
surgery (p = 0.026) or DCP ? enucleation (p = 0.043)
and secretin test positive at follow-up (p = 0.028); in cases
diagnosed as gastrinoma, the likelihood of disease pro-
gression was higher than cases with other GEP-NET
(p = 0.084). In the subgroup of 50 patients operated for
GEP-NET, the Kaplan–Meier curve showing GEP-NET
progression (follow-up from primary surgery) is shown in
Fig. 3b.
Adopting the log-rank method (Mantel-Cox) on 27
patients not operated on for GEP-NET, variables
Table 4 Non-surgical group data (27 patients)
No. of non-surgical patients 27 (28.6%) [8M (29.6%), 19F (70.4%)]
Mean age at MEN1 diagnosis 35.6 yrs (SD = 14.4); over 30 = 17 pts (63%); diagnosed before 1996: 9 (33.3%)
Mean age at GEP-NET diagnosis 45.4 yrs (SD = 15.3); over 30 = 23 pts (85.1%); diagnosed before 1996: no cases
Mean MEN1 GEP-NET diagnostic interval time 9 years
Syndromic symptoms 1 case (3.7%)
Mean follow-up from MEN1 diagnosis 15 years (SD = 10.5)
Mean follow-up from GEP-NET diagnosis 5.2 years (SD = 2.9)
Positive familial history 23 (85.2%)
Positive secretin test 21 (77.8%)
Type of positive hormone
Gastrin 12 pts
Glucagon 5 pts
VIP 1 pt
NSE, PP, CgA 3 pts
GEP-NET progression 12 pts (44.4%)
Increase in number or syndrome development 10 pts (83.3%)
Increase in volume 2 pts (16.7%)
Evidence of liver or lymph node metastasis 0 pts (0%)
Mean progression time 3.3 years (range 1–13)
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significantly associated with progression (follow-up after
MEN1 diagnosis) were male gender (p = 0.012) and
MEN1 diagnosis before 1996 (p = 0.001). Mutation in
exon 4 and double mutation of MEN1 did not reach sig-
nificance (p = 0.056 and 0.064, respectively). Figure 3c
shows Kaplan–Meier curve for GEP-NET progression in
this subgroup of 27 patients (follow-up from MEN1
diagnosis).
Globally, the log-rank method (Mantel-Cox) on all 77
patients found the following variables significantly asso-
ciated with mortality after GEP-NET diagnosis: MEN1
mutation in exon 8 (p = 0.001), DCP as first treatment
(p = 0.017), presence of liver metastases at the first
operation (p = 0.007), need for further surgery for liver
metastasis (p = 0.001), presence of postoperative compli-
cations (p = 0.02), age at last follow-up [50 years
(p = 0.036). Male gender (p = 0.09), positive preopera-
tive secretin test (p = 0.088), presence of gastrinoma
(p = 0.08) and positive secretin test at follow-up
(p = 0.09) did not reach statistical significance. The
overall survival Kaplan–Meier curve from the date of
diagnosis of GEP-NET in all 77 patients is shown in Fig. 4.
Discussion
The gene MEN1 was cloned only 15 years ago, and the
genetic test is still negative in 10% of MEN1 families [30].
This is also confirmed by our data, as the 12.99% of the
cohort had a negative MEN1 genetic test. In MEN1 syn-
drome, no clear genotype/phenotype correlation has been
described yet, but our data show MEN1 mutation in exon 8
associated with both GEP-NET progression and mortality.
Interestingly, the studied population is a representative
sample of Italian people affected by MEN1, since treated
patients were referred to our center from various national
hospitals. However, referring to epidemiological aspects
(age at diagnosis, sex ratio and the prevalence of GEP-NET
lesions) the reported cohort does not differ greatly from
other international case studies, such as the 233 patients
with MEN1 followed at the Mayo Clinic [27].
Since it is well known that GEP-NET is the leading
cause of disease-related deaths in patients with MEN1, this
study aims to assess the impact of various histological
types of GEP-NET on the outcome. Our data showed an
increased risk of progression and death in patients with
gastrinoma (all four patients who died were suffering from
that tumor). Potential bias in this evaluation is the fact that
a mean of 17.1 NF GEP-NET lesions were found at the
macro- and microscopic analysis of the surgical specimen
of the operated patients, and in 16 cases, those NF tumors
were [1.5 cm in diameter. Some studies in fact demon-
strate that NF GEP-NET lesions seem to be as aggressive
as gastrinomas or even more [25–27, 31–33]. However,
such aspect, which could be explained by a late diagnosis
due to the absence of clinical symptoms, needs to be
carefully assessed by future prospective studies carried out
in specialized centers, in which secretin stimulation test
and specific radiologic examinations are routinely per-
formed, and immunohistochemistry is adequately con-
ducted for GEP-NET analysis. In our series, the 4 patients
affected only by NF GEP-NET showed no statistically
different outcome compared to the patients with function-
ing GEP-NET associated with NF GEP-NET.
Notably, we surgically treated patients with MEN1
avoiding conservative approaches but aiming to grant
Table 5 Risk factors (and relative confidence intervals) for GEP-NET progression observed in the study group (77 pts) by using the log-rank
method (Mantel-Cox)
Risk factor Confidence interval Hazard ratio p value
Gender male Male versus female
14.2–25.2 versus 24.1–32.2
2.22 0.035
Mutation in exon 8 of MEN1 gene Mutation in exon 8 versus other mutation
14.9–26.1 versus 24.4–28.0
1.89 0.036
Diagnosis of MEN1 before 1996 Diagnosis before 1996 versus after 1996
13.4–18.2 versus 28.4–35.9
9.76 0.001
Surgery for GEP-NET Surgery for GEP-NET versus other treatment
20.5–26.3 versus 25.3–29.3
1.52 0.021
Type of operation (enucleation) Enucleation versus other
19.7–23.9 versus 24.1–28.3
1.49 0.026
Type of operation (PD ? enucleation) PD ? enucleation versus other
19.2–24.3 versus 23.5–28.8
2.44 0.043
Positive secretin test at follow-up Positive secretin test versus negative secretin test
18.2–22.8 versus 24.1–27.9
1.18 0.028
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Fig. 3 a Kaplan–Meier curve
showing oncologic progression
in 77-patient cohort starting
from time of diagnosis of GEP-
NET. b Kaplan–Meier curve
describing the oncologic
progression in 50 operated
patients with follow-up
calculated from primary
surgery. c Kaplan–Meier curve
describing the oncologic
progression in 27 non-operated
patients with follow-up
calculated from diagnosis of
MEN1
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oncologic radicality. In fact, among the 50 operated
patients, disease progression of GEP-NET occurred in 32%
of cases, after a mean postsurgical follow-up of 6.6 years.
Insulinoma in MEN1 seems to be less aggressive than other
types of GEP-NET, as none of the affected patients died
during follow-up. Such behavior does not seem to be
related to a size criterion (insulinomas are usually larger
than 1.5 cm), but maybe to an earlier diagnosis and treat-
ment because of the important clinical syndrome; another
hypothesis suggests that a greater differentiation might be
responsible for the indolent behavior [34]. However, the
constant association with NF lesions observed in our cases
highlights the need of further studies to assess the conse-
quences of limiting the treatment of these cases to the
simple enucleation of the insulinoma.
In our study, we also performed the statistical evaluation
according to the size of the tumors (diameter\
or[ 1.5 cm, respectively) and the presence of lymph node
and/or liver metastases. Only the presence of liver metas-
tases and liver surgery had a significant impact on survival.
Therefore, it is very important to differentiate between
benign and malignant liver lesions, although differential
diagnosis can be extremely difficult despite preoperative
targeted imaging studies (MRI with liver-specific contrast).
Therefore, an aggressive surgical attitude in patients with
synchronous liver lesions could be of both diagnostic and
prognostic value. Age at GEP-NET primary surgery was
under 50 years in the vast majority of patients, thus sup-
porting the need for an accurate evaluation and treatment
of liver lesions.
Concerning the adrenal lesions and carcinoids, in our
study they were not shown to increase significantly the risk
of mortality. No deaths directly related to the adrenal gland
involvement were recorded. These results, however, do not
confirm what was already reported by Skogseid [35] and
Langer [36], who observed a significant rate of adrenal
hyperplasia evolution toward highly aggressive carcinomas
in MEN1. One patient in our series died in 2000 at age 52
for recurrence of thymic carcinoid.
A statistical strength but also a possible limit of the
present study is the long period of observation; in fact, it
might introduce statistical bias due to epocal variations
in MEN1 clinical management (diagnostic tools and
therapeutic strategies); however, the mono-centric nature
of the present study contributed to minimize the bias, as
the patients were followed/treated by the same medical
team. The statistical analysis took into account the per-
iod of diagnosis of MEN1 and GEP-NET, and the date of
surgery, in order to accurately define the impact of each
lesion on the risk of disease progression and death.
Notably, a significant decrease in GEP-NET progression
was observed in patients diagnosed with MEN1 after
1996, while age at follow-up over 50 was a significant
risk factor for mortality, and a diagnosis of MEN1 before
1996 was more correlated with disease progression. This
suggests that time has a key role in GEP-NET progres-
sion, even in operated patients and independently of the
type of pancreatic surgery performed primarily. In fact,
in our experience, both enucleation of GEP-NET and PD
associated with enucleation were statistically related to
disease progression. This aspect was adequately ana-
lyzed during the long postoperative follow-up in our
series.
Goudet [28] found that the prognosis of MEN1 syn-
drome has improved regularly since 1980, with a slight
decrease in MEN1-related mortality over time, respec-
tively, 76.8 and 71.4% before and after 1990. This might
be due to the drastic reduction in operative mortality and
the virtual disappearance of deaths related to complica-
tions of ZES (perforation and/or bleeding). These mor-
tality rates are, however, quite high compared to
previous experiences reporting MEN1-related death
rates between 28 and 46% [25–27]. Different length of
median follow-up of these studies may explain this dis-
crepancy. Ito [10] described NIH experience about 106
cases of ZES in MEN1 reporting 23% mortality at 24.5-
year follow-up with no mortality linked to acid hyper-
secretion complications: Even if the surgical approach
they adopted is not reported in details, in our cohort
mortality rate is lower, allegedly due to the shorter mean
follow-up time. In MEN1 GEP-NET (particularly in case
of ZES), we prefer to perform aggressive surgery
including regional lymphadenectomy, in order to remove
all functioning tumors (and potentially functioning tis-
sue) as well as every lesion larger than 1.5 cm.
Fig. 4 Kaplan–Meier curve showing overall survival of 77 patients
with follow-up calculated from the time of diagnosis of GEP-NET
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In our series, though the low MEN1-related mortality
rate (5.2%), we found, as expected, the presence of
familiar history of MEN1 to have a protective effect on
the risk of death, probably leading to an earlier diagnosis
and surgery for GEP-NET. However, this factor had the
opposite effect on the risk of progression, particularly in
patients operated for GEP-NET. A possible explanation is
the phenomenon of the anticipation linked to the genetic
transmission.
Interestingly, regarding time, even in presence of a
similar follow-up from MEN1 diagnosis (15 vs. 16.6 years
in non-surgical and surgical cohorts, respectively), the
behavior of GEP-NET seems heterogeneous, since some
patients did not reach the surgical criteria, while in other
cases, a disease progression occurred.
Even if secretin stimulation test is not considered a
parameter to indicate surgery, we regularly performed it in
the clinical management of patients: Our results show that
a positive test is significantly related to the risk of pro-
gression, indicating its diagnostic sensibility and potential
utility in the pre- and postoperative follow-up, especially to
obtain a timely detection of GEP-NET hormone produc-
tion, allowing both an early and potentially more accurate
diagnosis and treatment.
Conclusion
The present paper, describing single-center data about
MEN1 GEP-NET epidemiologic, clinical and pathological
features, allows to clarify their natural history: GEP-NET
are often multiple but surgically curable and tend to pro-
gression over time, even after surgery. Still unknown fac-
tors let them be clinically more aggressive in some patients
(who require surgery) than in other. Scheduled surveillance
allows a prompt surgical therapy able to minimize the rate
of mortality.
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